ERBB2 and invasive breast carcinoma: Triple-negative breast cancer (TNBC) accounts for 10 to 20% of all invasive breast cancer (BrCa) cases and lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) responsiveness.